Hyperplasia News and Research RSS Feed - Hyperplasia News and Research

Implementation of video-based decision aids influences care decisions in urology

Implementation of video-based decision aids influences care decisions in urology

After Group Health Cooperative implemented video-based decision aids for men with two common prostate conditions, rates of elective surgery for benign prostatic hyperplasia (BPH) and rates of active treatment for localized prostate cancer declined over six months. [More]
Women diagnosed with DCIS or atypia should seek second opinions, says study

Women diagnosed with DCIS or atypia should seek second opinions, says study

While doctors almost always agree on a pathological diagnosis of invasive breast cancer, there is room for improvement when diagnosing atypia (or atypical ductal hyperplasia-ADH) and DCIS (ductal carcinoma in-situ), Anna Tosteson, ScD and Tracy Onega, PhD from Dartmouth-Hitchcock's Norris Cotton Cancer Center have found. [More]
Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the commercial availability of NATESTO (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. [More]
Blunted cortisol response common in non-classic CAH

Blunted cortisol response common in non-classic CAH

Nearly two-thirds of children with non-classic congenital adrenal hyperplasia have an inadequate cortisol response, report researchers. [More]
Cost of care for benign prostate hyperplasia measured for the first time

Cost of care for benign prostate hyperplasia measured for the first time

UCLA researchers have for the first time described cost across an entire care process for a common condition called benign prostate hyperplasia (BPH) using time-driven activity-based costing. They found a 400 percent discrepancy between the least and most expensive ways to treat the condition. [More]
VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has initiated a pilot study to assess the feasibility of VolitionRx's proprietary NuQ assays in detecting prostate cancer. [More]
Breakthrough treatment option for men with benign prostatic hyperplasia

Breakthrough treatment option for men with benign prostatic hyperplasia

Men with benign prostatic hyperplasia (BPH), a condition in which the prostate is enlarged but not cancerous, have a new, breakthrough treatment option that is less invasive and has fewer complications than other minimally invasive treatments, such as transurethral resection of the prostate and surgical options, according to research presented at the Society of Interventional Radiology's Annual Scientific Meeting. [More]
Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Endo International plc today reported fourth quarter 2014 revenues of $800 million, an increase of 37 percent compared to fourth quarter 2013 revenues of $585 million, including new product revenue from 2014 strategic M&A transactions. [More]
Second opinions can optimize outcomes and avoid needless expenses

Second opinions can optimize outcomes and avoid needless expenses

Mary Rockland was in a panic when she learned that she was diagnosed with invasive breast cancer. Like many patients, she trusted her doctor when he told her that a lump in her breast was cancerous, and relied on his judgment when he recommended a bilateral mastectomy. [More]
Study focuses on two natural approaches to preventing breast cancer

Study focuses on two natural approaches to preventing breast cancer

Preventing cancer requires intimate knowledge of how cancer starts, what causes it to grow and flourish, and how to stop it in its tracks. Sometimes this comes in the form of a vaccine (the HPV vaccine for cervical and head and neck cancers), a screening (a colonoscopy for colorectal cancer) or a blood test (the PSA level test for prostate cancer). [More]
AMS sponsors ‘Healthy Body Healthy Mind’ series to promote awareness on stress urinary incontinence

AMS sponsors ‘Healthy Body Healthy Mind’ series to promote awareness on stress urinary incontinence

American Medical Systems Inc. (AMS), a subsidiary of Endo International plc and leading provider of medical technologies for pelvic health, is proud to be a sponsor of an episode of the popular Healthy Body Healthy Mind series titled "Managing Female Stress Urinary Incontinence." [More]
FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States. [More]
Breast cancer risk for women with atypical hyperplasia greater than previously thought, study finds

Breast cancer risk for women with atypical hyperplasia greater than previously thought, study finds

Women with atypical hyperplasia of the breast have a higher risk of developing breast cancer than previously thought, a Mayo Clinic study has found. Results of the study appear in a special report on breast cancer in the New England Journal of Medicine. [More]
Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation. [More]
Surgical membrane delivers healing action of vitamin A

Surgical membrane delivers healing action of vitamin A

When blood vessels are damaged through surgery, it can trigger an endless cycle of scarring and repair. [More]
Men with BPH need to discuss 'male orgasmic dysfunction' with doctors prior to any treatment

Men with BPH need to discuss 'male orgasmic dysfunction' with doctors prior to any treatment

NeoTract, Inc., today welcomes the publication of a paper in the British Journal of Urology International which calls for men suffering from enlarged prostate to discuss with their doctors the likely impact of treatment options on their sexual function. Most procedures and many medications can cause sexual dysfunction. Clinical studies show that treatment with the UroLift system has not been associated with any new onset of sustained ejaculatory or erectile dysfunction. [More]
Rare neuroendocrine tumours may be misdiagnosed as Cushing’s disease

Rare neuroendocrine tumours may be misdiagnosed as Cushing’s disease

Ectopic tumours secreting corticotropin-releasing hormone and adrenocorticotropic hormone are very rare in children and can result in a misdiagnosis of Cushing’s disease, say researchers. [More]
UW-Madison receives $8.3 million NIH grant to create new urological research center

UW-Madison receives $8.3 million NIH grant to create new urological research center

The University of Wisconsin-Madison has been awarded an $8.3 million grant from the National Institutes of Health to create a research center focused on urological health. [More]

Urologists evaluate physician adherence to AUA's BPH/LUTS guidelines

Evidence-based guidelines play an increasing role in setting standards for medical practice and quality but are seldom systematically evaluated in the practice setting. Investigators evaluated the rate of physician adherence to the American Urological Association's guidelines on the management of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) to establish a benchmark for future research. [More]
RNA molecules in tissue, urine samples can detect prostate cancer

RNA molecules in tissue, urine samples can detect prostate cancer

Researchers at Sanford-Burnham Medical Research Institute have identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients but not in normal healthy individuals. [More]
Advertisement
Advertisement